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Table. XIENCE V Planned Overlap for Very Long Coronary Lesions (Pooled SII,
SIII, SIV, SV, Small Vessel, XV USA)
> 24 to < 35 mm
Lesion Length
(N=482)
(L=500)
 35 mm
Lesion Length
(N=323)
(L=328)
p-value
> 24 to
< 35 mm
vs.  35 mm
Per Lesion
Analysis (baseline)
Mean Lesion
Length (mm)
28.07  2.44 (500) 47.06  13.69 (328) <0.0001
Mean Total Stent
Length (mm)
41.0  9.0 (500) 56.1  17.6 (328) <0.0001
Per Subject
Analysis (1-year)
Hierarchical
Subject Counts
TLF 10.1% (47/466) 9.0% (28/311) 0.7102
MACE 10.1% (47/466) 9.3% (29/311) 0.8056
Non-Hierarchical
Subject Counts
All Death 2.8% (13/466) 4.2% (13/311) 0.3132
Cardiac Death 2.1% (10/466) 2.3% (7/311) 1.0000
All MI 3.9% (18/466) 4.8% (15/311) 0.5869
Target Vessel MI 3.6% (17/466) 4.5% (14/311) 0.5780
ID/CI-TLR 5.6% (26/466) 5.1% (16/311) 0.8721
ARC Stent Thrombosis
Deﬁnite 0.7% (3/454) 1.0% (3/307) 0.6898
Deﬁnite/Probable 1.5% (7/454) 1.6% (5/307) 1.0000
TLF ¼ cardiac death, target vessel MI, ID/CI-TLR; MACE ¼ cardiac death, all MI, ID/CI-TLR
P-values for per lesion analyses are from t-test; P-values for per subject analyses are from
Fisher's exact test; All p-values displayed are two-tailed and not from pre-speciﬁed hypothesis
testing and are displayed for information only
Denominators for per subject analyses (except for Arc Stent Thrombosis) exclude subjects
who are truly lost-to-follow-up, deﬁned as subjects who are lost to follow-up through given
timepoint without any DMR event (all death, all MI, all revascularization).
ARC stent thrombosis denominators exclude subjects who were early terminated and did not
have deﬁnite or probable ARC stent thrombosis
WHO-based per protocol deﬁnitions were used for MI except for SPIRIT V, where ARC MI
deﬁnitions were used
For per lesion analysis, only lesions with planned overlapping stents were included.
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Background: The current study compared the novel Biotronik Osiro stent, eluting
sirolimus from a biodegradable polymer PLLA, applied on a thin-strut (60 mm)
Silicon-Carbide coated Cobalt-Chromium stent with the Abbott Xience PrimeTM
stent. The primary endpoint was non-inferiority for in-stent Late Lumen Loss (LLL) at
9 months in de novo coronary artery lesions.
Methods: We performed a prospective, multicenter, randomized controlled study
(RCT) in 452 subjects (63.410.0 yrs) with symptomatic coronary artery disease due
to de novo stenotic lesions in native coronary arteries with a RVD  2.25 mm, Ø 4.0
mm and a lesion length  26 mm. Subjects were randomly assigned 2:1 to receive the
Osiro SES or the Xience Prime EES. The primary endpoint of the study is in-stent
LLL assessed at 9 months and analyzed according to the intention-to-treat principle.
All subjects were enrolled between July 5, 2011- March 23, 2012 and were invited to
undergo repeat angiography at 9 months. Clinical follow up visits are performed at 1,
6, 12 months and annually for up to 5 years after the procedure. All angiographic
images were analyzed by (R. Waksman, Medstar, Washington DC, USA). All clinical
events were adjudicated by 3 independent cardiologists (MD:s). Clinicaltrials.gov no.
NCT01356888
Results: Both study groups showed comparable populations in terms of demo-
graphics, current risk factors, clinical history and lesion/vessel characteristics. The in-
stent late lumen loss at 9-months was 0.10  0.32 mm for the Osiro compared to 0.11
 0.29 mm for the Xience with a p-value of 0.9849. The non-inferiority hypothesis
was thereby conﬁrmed with p-value<0.0001. The clinical endpoint of Target Lesion
Failure (TLF) at 9 month was 4.8% for the Osiro compared to 5.3% for the Xience
with a p-value of 0.9849.
Conclusions: In this RCT the Osiro SES with a biodegradable polymer was non-
inferior to the Xience Prime EES with a durable polymer for the primary angio-
graphic endpoint of in-stent late loss at 9 months. Clinical event rates were low and
comparable with both Osiro and Xience Prime through 9 months. Results of the
clinical event rates at 12 month are now being analyzed and will be presented at the
meeting for the ﬁrst time.
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Background: Very long ( 35 mm) coronary lesions are more complex than shorter
lesions. Single-stent treatment of very long coronary lesions is limited by maximum
stent length, and since stents in the everolimus-eluting cobalt-chromium XIENCE
family of coronary stents with lengths > 28 mm have only recently become available,
a predetermined planned overlap strategy is most often used for treatment of lesions 
35 mm in length. There is a substantive body of clinical data for XIENCE V (Abbott
Vascular, Santa Clara), but outcomes for very long coronary lesions using Xience V
have not previously been reported.
Methods: The pooled "XIENCE V Planned Overlap" dataset combines patients
treated using XIENCE V with a predetermined planned overlap strategy from six
prospective multi-center trials: SPIRIT II, SPIRIT III, SPIRIT IV, SPIRIT V, SPIRIT
Small Vessel, and XIENCE V USA. Analyses were performed on subjects with
lesions > 24 to < 35 mm in length and  35 mm in length. Clinical outcomes
evaluated at 1 year included TLF and MACE, all death, cardiac death, all MI, target
vessel MI, ID/CI-TLR, and deﬁnite and deﬁnite/probable stent thrombosis. All
endpoint events were adjudicated by independent clinical evaluation committees.
Results: There were 482 patients with 500 lesions > 24 to < 35 mm in length, and
323 patients with 328 lesions  35 mm in length. The Table shows that 1-yearB56 JACC Vol 62/18/Suppl B j October 27–November 1, 2013outcomes were not signiﬁcantly different in very long lesions compared to those > 24
to < 35 mm.
Conclusions: Despite inherent increased complexity of very long coronary lesions,
XIENCE V PCI treatment resulted in similar clinical outcomes at 1 year for very long
( 35 mm) coronary lesions as for shorter (> 24 to < 35 mm) lesions. Based on these
clinical data, XIENCE V PCI treatment of lesions  35 mm appears as effective and
safe as PCI for shorter lesions.TCT-175
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Background: Patients with diabetes mellitus were shown to have less favorable
outcomes after saphenous vein graft (SVG) intervention with bare metal stents while
its impact with drug-eluting stents (DES) is not clearly deﬁned. We aimed to compare
clinical outcomes in diabetic patients who underwent SVG percutaneous coronary
interventions (PCI) with the use of DES.
Methods: From our PCI registry we retrospectively analyzed 477 consecutive patients
with prior CABG who underwent SVG PCI with the implantation of DES stratiﬁed by
presence or absence of diabetes. The primary end point was 1-year major cardiac eventj TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
